| Revision as of 07:41, 2 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation← Previous edit |
Latest revision as of 15:30, 12 January 2025 edit undoArthurfragoso (talk | contribs)Extended confirmed users, Template editors4,591 edits dark mode fix |
| (86 intermediate revisions by 42 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Combination drug for HIV}} |
|
{{Drugbox |
|
|
|
{{Infobox drug |
| ⚫ |
| verifiedrevid = 424656191 |
|
|
|
| Verifiedfields = changed |
|
⚫ |
| verifiedrevid = 448004176 |
|
|
| image = Abacavir and lamivudine.svg |
|
|
| image_class = skin-invert-image |
|
|
| width = 200 |
|
|
|
|
|
<!--Combo data--> |
|
<!--Combo data--> |
| Line 10: |
Line 15: |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = Kivexa, Epzicom, others |
|
|
| Drugs.com = {{drugs.com|ppa|abacavir-and-lamivudine}} |
|
| MedlinePlus = a696011 |
|
| MedlinePlus = a696011 |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = B3 |
|
⚫ |
| pregnancy_category = |
|
| pregnancy_US = C |
|
|
⚫ |
| routes_of_administration = ] |
| ⚫ |
| pregnancy_category = |
|
|
⚫ |
| ATC_prefix = J05 |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
|
⚫ |
| ATC_suffix = AR02 |
| ⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
|
|
|
|
|
<!-- Legal status --> |
|
|
| legal_AU = S4 |
|
|
| legal_AU_comment =<ref>{{cite web | title=CAVADEXA, ABADINE, ABALAMID HETERO, BACAMID, LAMAVIR 600/300 (Hetero Australia Pty Ltd) | website=Therapeutic Goods Administration (TGA) | date=13 January 2023 | url=https://www.tga.gov.au/resources/prescription-medicines-registrations/cavadexa-abadine-abalamid-hetero-bacamid-lamavir-600300-hetero-australia-pty-ltd | access-date=15 April 2023}}</ref> |
|
|
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F --> |
|
|
| legal_BR_comment = |
|
|
| legal_CA = Rx-only |
|
|
| legal_CA_comment = |
|
|
| legal_DE = <!-- Anlage I, II, III or Unscheduled --> |
|
|
| legal_DE_comment = |
|
|
| legal_NZ = <!-- Class A, B, C --> |
|
|
| legal_NZ_comment = |
|
| legal_UK = POM |
|
| legal_UK = POM |
|
|
| legal_UK_comment = |
|
| legal_US = Rx-only |
|
| legal_US = Rx-only |
|
|
| legal_US_comment = |
|
| legal_status = |
|
|
|
| legal_EU = Rx-only |
| ⚫ |
| routes_of_administration = Oral |
|
|
|
| legal_EU_comment = <ref>{{cite web | title=Kivexa EPAR | website=] | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa | access-date=16 November 2020}}</ref> |
|
⚫ |
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
|
|
| legal_UN_comment = |
|
|
| legal_status = <!-- For countries not listed above --> |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
| CAS_number = |
|
| CAS_number = 136470-78-5 |
| ⚫ |
| ATC_prefix = J05 |
|
|
|
| CAS_number2_Ref = {{cascite|correct|CAS}} |
| ⚫ |
| ATC_suffix = AR02 |
|
|
|
| CAS_number2 = 134678-17-4 |
|
| PubChem = 5273759 |
|
| PubChem = 5273759 |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = |
|
| DrugBank = |
|
| DrugBank = |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = WR2TIP26VS |
|
|
| UNII2_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII2 = 2T8Q726O95 |
|
|
| KEGG = D08775 |
|
|
| NIAID_ChemDB = 225604 |
|
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
}} |
|
}} |
|
'''Abacavir/lamivudine''' (]) is a ] for the treatment of ]. It is marketed as '''Kivexa''' in most countries except for the United States, where it is branded as '''Epzicom'''.<ref></ref> It is a ] of ] (3TC, Epivir) and ] (ABC, Ziagen). |
|
|
|
|
|
|
|
<!-- Definition and medical uses --> |
|
Lamivudine and abacavir are both ]s (NRTI). |
|
|
|
'''Abacavir/lamivudine''', sold under the brand name '''Kivexa''' among others, is a ] ] used to treat ].<ref name=PI2016/> It contains ] and ].<ref name=PI2016/> It is generally recommended for use with other ].<ref name=PI2016/> It is commonly used as part of the preferred treatment in children.<ref name=WHO2015Use>{{cite book | vauthors = ((World Health Organization)) | year = 2015 | title = The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children) | publisher = World Health Organization | location = Geneva | author-link = World Health Organization | hdl = 10665/189763 | id = WHO technical report series;994 | hdl-access=free | isbn = 9789241209946 | issn = 0512-3054 |pages=45–46 }}</ref> It is taken by mouth as a tablet.<ref name=PI2016>{{cite web|title=Abacavir and Lamivudine Tablets|url=https://www.drugs.com/pro/abacavir-and-lamivudine-tablets.html|publisher=Teva Pharmaceuticals USA|access-date=28 November 2016|url-status=live|archive-url=https://web.archive.org/web/20170206022505/https://www.drugs.com/pro/abacavir-and-lamivudine-tablets.html|archive-date=6 February 2017}}</ref> |
|
|
|
|
|
|
<!-- Side effects and mechanism --> |
|
It was approved by the FDA on August 2, 2004. It is marketed by ]. |
|
|
|
Common side effects include ], ], ], ], ], ], and fever.<ref name=PI2016/> Serious side effects may include ], ]s, and ].<ref name=PI2016/> It is not recommended in people with a specific ] known as ].<ref name=PI2016/> Safety in ] has not been well studied but it appears to be okay.<ref>{{cite web|title=Abacavir / lamivudine (Epzicom) Use During Pregnancy|url=https://www.drugs.com/pregnancy/abacavir-lamivudine.html|website=www.drugs.com|access-date=4 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161220201915/https://www.drugs.com/pregnancy/abacavir-lamivudine.html|archive-date=20 December 2016}}</ref> Lamivudine and abacavir are both ]s (NRTI).<ref name=PI2016/> |
|
|
|
|
|
<!--History and culture --> |
|
|
Abacavir/lamivudine was approved for medical use in the United States in 2004.<ref name=PI2016/> It is on the ].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref> |
|
|
|
|
|
==Society and culture== |
|
|
===Names=== |
|
|
It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom.<ref>{{Cite web|url=https://viivhealthcare.com/viiv-hiv-medicines/|archiveurl=https://web.archive.org/web/20091207235357/http://www.viivhealthcare.com/en/products/epzicom-kivexa.aspx|url-status=dead|title=Our HIV medicines|archivedate=7 December 2009|website=viivhealthcare.com|accessdate=15 April 2023}}</ref> |
|
|
|
|
|
===Legal challenges=== |
|
|
] and ] both filed ]s (ANDAs) relating to the treatments of HIV using various combinations of abacavir, lamivudine and AZT, and challenging various patents. In 2013 the US District Court for the District of Delaware upheld the validity of a patent covering Epzicom and Tizivir. Other matters were subject to appeal or litigation as of 20 November 2014.<ref>{{Cite web|publisher=Glaxosmithkline|url=http://www.gsk.com/media/560424/gsk-novartis-circular.pdf|title=PROPOSED MAJOR TRANSACTION WITH NOVARTIS AG:Circular to Shareholders and Notice of General Meeting|date=20 November 2014|url-status=dead|archive-url=https://web.archive.org/web/20150203213849/http://www.gsk.com/media/560424/gsk-novartis-circular.pdf|archive-date=2015-02-03|access-date=2015-02-03}}</ref> |
|
|
|
|
|
==See also== |
|
|
* ], brand name Trizivir |
|
|
* ], brand name Triumeq |
|
|
|
|
|
==References== |
|
==References== |
|
{{Reflist}} |
|
{{Reflist}} |
|
{{HIVpharm}} |
|
|
|
|
|
|
|
==External links== |
| ⚫ |
] |
|
|
|
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/abacavir%20mixture%20with%20lamivudine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Abacavir mixture with lamivudine }} |
|
|
|
|
|
|
{{Antiretroviral drug}} |
|
|
{{Portal bar | Medicine | Viruses }} |
|
|
|
|
|
|
{{DEFAULTSORT:Abacavir Lamivudine}} |
|
{{antiinfective-drug-stub}} |
|
|
⚫ |
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |